Hepatocystin contributes to interferon-mediated antiviral response to hepatitis B virus by regulating hepatocyte nuclear factor 4α  by Shin, Gu-Choul et al.
Biochimica et Biophysica Acta 1842 (2014) 1648–1657
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isHepatocystin contributes to interferon-mediated antiviral response to
hepatitis B virus by regulating hepatocyte nuclear factor 4αGu-Choul Shin a,b, Sung Hyun Ahn a, Hyo-Sun Choi a, Jingyeong Kim a, Eun-Sook Park a,
Doo Hyun Kim a, Kyun-Hwan Kim a,b,c,⁎
a Department of Pharmacology and Center for Cancer Research and Diagnostic Medicine, IBST, School of Medicine, Konkuk University, Seoul, Republic of Korea
b Institute of Functional Genomics, Konkuk University, Seoul, Republic of Korea
c Research Institute of Medical Sciences, Konkuk University, Seoul, Republic of Korea⁎ Corresponding author at: Department of Pharma
Research and Diagnostic Medicine, IBST, Konkuk Uni
Hwayang-dong, Kwangjin-gu, Seoul 143-701, Republic of
fax: +82 2 2049 6192.
E-mail address: khkim10@kku.ac.kr (K.-H. Kim).
http://dx.doi.org/10.1016/j.bbadis.2014.04.016
0925-4439/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 January 2014
Received in revised form 6 April 2014
Accepted 13 April 2014
Available online 25 April 2014
Keywords:
Hepatocystin
Hepatitis B virus
Interferon
HNF4α
MAPKHepatocystin/80K-H is known as a causative gene for autosomal dominant polycystic liver disease. However, the
role of hepatocystin in hepatitis B virus-related liver disease remains unknown. Here, we investigated the role of
hepatocystin on the cytokine-mediated antiviral response against hepatitis B virus infection.We investigated the
antiviral effect and mechanism of hepatocystin by ectopic expression and RNAi knockdown in cell culture and
mouse livers. Hepatocystin suppressed the replication of hepatitis B virus both in vitro and in vivo. This inhibitory
effect was HBx-independent andmediated by the transcriptional regulation of viral genome via the activation of
exogenous signal-regulated kinase 1/2 and the reduced expression of hepatocyte nuclear factor 4α, a transcrip-
tion factor essential for hepatitis B virus replication. The amino-terminal region of hepatocystin was essential for
regulation of this antiviral signaling pathway. We also found that hepatocystin acts as a critical component in
interferon-mediated mitogen-activated protein kinase signaling pathway, and the interferon-induced antiviral
activity against hepatitis B virus is associated with the expression levels of hepatocystin. We demonstrated
that hepatocystin plays a critical role inmodulating the susceptibility of hepatitis B virus to interferon, suggesting
that the modulation of hepatocystin expression is important for cytokine-mediated viral clearance during hepa-
titis B virus infection.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hepatitis B virus (HBV) infection is a major risk factor in chronic
hepatitis, liver ﬁbrosis, and hepatocellular carcinoma [1], and it re-
mains a major public health problem worldwide [2]. HBV is a small,
enveloped DNA virus with a genome size of 3.2 kb. HBV replicates
its partially double-stranded DNA genome within core particles by
reverse transcription of encapsulated 3.5-kb pregenomic RNA [3].
Viral transcription is regulated by hepatocyte-enriched transcription
factors such as hepatocyte nuclear factor (HNF)1, HNF3, HNF4, and
cofactor PGC-1 [4–7].
Interferon (IFN)-α/β and IFN-γ inhibit HBV replication non-
cytopathically during viral infection [8,9]. IFNs can control HBV replica-
tion through a variety of mechanisms. First, IFN inhibits HBV replication
by preventing the formation of virus RNA-containing core particles, and
reducing the accumulation of viral replicative intermediates with nocology and Center for Cancer
versity School of Medicine, 1
Korea. Tel.: +82 2 2080 7833;signiﬁcant changes in viral mRNA levels [8,9]. Alternatively, it has
been reported that IFN reduces virus replication through transcriptional
and posttranscriptional regulation of the HBV genome [10]. However,
the molecular mechanisms through which IFNs mediate these different
effects are unknown. IFN-induced antiviral action is primarily mediated
by the activation of the Janus kinase (JAK) and its downstream signal
transducer and activator of transcription (STAT) signaling and the
induction of IFN-stimulated genes (ISGs) such as 2′,5′-oligoadenylate
synthetase (OAS), protein kinase R (PKR), and MX1 [11]. Notably, a
recent study suggests that HBV counteracts and interferes with these
antiviral signaling pathways [12]. Moreover, those ISGs are not involved
in the antiviral response in a HBV transgenic mouse and cell model [13,
14], suggesting the possible existence of other IFN-induced antiviral
mediators. IFNs also modulate the activity of other cellular kinases and
transcriptional regulators, including nuclear factor-kappa B (NF-κB)
andmitogen-activated protein kinase (MAPK) family members, includ-
ing extracellular signal-regulated kinase (ERK1/2) and stress-activated
protein kinase 1/c-jun NH2-terminal kinase (SAPK/JNK) [15]. These sig-
naling pathways have also been shown to play a role in the antiviral
response against HBV [16,17]. However, the precise role of these signal-
ing pathways in IFN-mediated antiviral response against HBV infection
has not been fully elucidated.
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strate, 80K-H [18]. Most of the previous reports on this protein have
focused onelucidating its role in thepathogenesis of autosomal dominant
polycystic liver disease (ADPLD) [19,20]. Hepatocystin functions as the
noncatalytic beta subunit of the alpha glucosidase II, which is involved
in the processing of newly synthesized glycoproteins within the endo-
plasmic reticulum [20]. We previously demonstrated that hepatocystin
can regulate HBV replication by destabilizing the HBV X (HBx) protein,
which is essential for viral replication [21]. However, the possible role
of this protein in HBV-mediated liver pathogenesis has not been fully
elucidated. Recent studies have shown that hepatocystin is a functional
component of a cytosolic signal transduction complex and interacts
with ﬁbroblast growth factor receptors, resulting in the regulation of
Ras/MAPK signaling [22,23]. Therefore, we speculated that hepatocystin
functions in the IFN-mediated inhibition of HBV replication by modulat-
ing the antiviral signaling pathway.
In the present study, we investigated the antiviral activity of
hepatocystin and the molecular mechanism of its action, focusing pri-
marily on its role in IFN-induced antiviral signaling pathways.2. Materials and methods
2.1. Reagents and plasmids
Anti-Flag M2 antibody and anti-GAPDH antibody were obtained
from Sigma (St. Louis, MO). Anti-hepatocystin antibody, anti-HNF4α
antibody, anti-HNF3β antibody, anti-PGC-1 antibody, and anti-HNF1α
antibody were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-HBV surface (HBs) antibody (Abcam, Cambridge, MA), anti-
HBx antibody (BioVender, Heidelberg, Germany), anti-phospho-ERK1/
2 antibody, anti-ERK1/2 antibody, anti-phospho-p38 antibody, anti-
p38 antibody, and anti-phospho-JNK1/2 antibody (Cell Signaling
Technologies, Beverly, MA) were used in this study. Alexa Fluor 350
anti-rabbit IgG secondary antibody and Alexa Fluor 546 anti-mouse
IgG secondary antibody were obtained from Invitrogen (Carlsbad, CA).
Anti-mouse and anti-rabbit antibodies conjugated with horseradish
peroxidase were purchased from Sigma. The MAPK inhibitors PD98059,
SB203580, and SP600125 were purchased from Calbiochem (La Jolla,
Ca). Human recombinant TNF-α, IFN-γ, and TGF-βwere obtained from
BioVision (Mountain View, CA), LG Life Science Co. (Korea), and R&D
Systems (Minneapolis, MN), respectively. The replication-competent
HBV construct, HBV1.2 (strain ayw), and the HBx-deﬁcient HBV con-
struct, HBV1.2 (X-), have been described previously [24] andwere kindly
provided by Dr W.S. Ryu (Yonsei University). Full-length wild type
hepatocystin and amino-terminal deletion mutants (M1 and M2) with
a C-terminal Flag-tag were inserted into the BamH I/Xba I site of the
pcDNA 3.1 vector as described previously [21]. The plasmid pEnhI.II-Luc
was constructed by insertion of the EnhI/Enh II-core promoter com-
plex (nt. 962–1802 of the HBV genome) into the pGL3-basic vector
(Promega). HNF4α expressing plasmid was constructed by insertion
of the human HNF4α gene (GenBank NM_178849) into the pcDNA
3.1 vector. The siRNA against hepatocystin (GGAAGAAGUCUCUGGAAG
AUU) and the predesigned negative control siRNA against GFP were
synthesized by ST Pharm Co. (Seoul, Korea).2.2. Cell culture and transient transfection
HepG2 and Huh-7 cells were maintained in DMEM (Gibco, Grand
Island, NY) supplemented with 10% heat-inactivated fetal bovine
serum, penicillin, and streptomycin in a 5% CO2 environment at 37 °C.
Transient transfections were performed using Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer's instructions. The
amount of plasmid DNA was normalized using an empty vector in all
transfection experiments.2.3. HBV surface antigen analysis
HepG2 and Huh-7 cells were transfected with the indicated plas-
mids using Lipofectamine 2000 reagent. At 4 days after transient trans-
fection, cells were lysed with RIPA buffer and then subjected to western
blot analysis using an anti-HBs antibody (Abcam) to determine the
expression levels of intracellular HBV surface antigen (HBsAg). To
measure secreted levels of HBsAg, culture media were collected and
analyzed using the Enzygnost HBsAg 5.0 System (Siemens Healthcare
Diagnostics, Marburg, Germany).2.4. Northern and Southern blot analyses
HepG2 and Huh-7 cells were transfected with the indicated plas-
mids using Lipofectamine 2000 reagent. At 4 days after transient
transfection, HBV viral RNA and replicative DNA intermediates
were detected by Northern and Southern blot analyses, respectively.
To detect HBV RNAs, total RNA was isolated from HepG2 cells using
TRIzol reagent (Invitrogen), and then 50 μg of total RNAwas separat-
ed by electrophoresis on a 1% formaldehyde-agarose gel, transferred
to a nylon membrane, and detected with an isotope-labeled HBV
probe. To detect HBV DNA intermediates, cells were lysed with HEPES
buffer as previously described [21]. Cell lysates were treated with
DNase I (Clontech/Takara Bio, Mountain View, CA) and mung bean
nuclease (Clontech/Takara) to eliminate transfected plasmid DNA.
Cytoplasmic HBV DNA was puriﬁed by digestion of capsid protein
with Proteinase K (20 mg/mL; Roche Applied Science, Indianapolis,
IN) at 37 °C for 2 h in the presence of SDS, phenol extraction, and
ethanol precipitation. Puriﬁed DNA was separated on a 1% agarose gel,
transferred onto a nylon membrane, and then detected with an isotope-
labeled HBV probe.2.5. Western blot analysis
Proteinswere extracted using RIPA buffer supplementedwith prote-
ase inhibitor cocktail (Sigma). Protein concentration was quantiﬁed
using the bicinchoninic acid method (Pierce, Rockford, IL). Proteins
were boiled in 1× sample buffer (10 mM Tris–HCl pH 6.8, 1% SDS, 5%
glycerol, 0.05% bromophenol blue, and 1% β-mercaptoethanol) for
5 min and separated on SDS-PAGE. Proteins were electrotransferred to
Immobilon-P membranes (Millipore Corp., Bedford, MA) and blotted
with the indicated antibodies at 4 °C overnight in Tris-buffered saline
containing 0.05% Tween 20 and 1% nonfat milk. Membranes were
then incubated with horseradish peroxidase-conjugated antibodies at
room temperature for 1 h, and the signal was detected using enhanced
chemiluminescence (Pierce). The band signal was detected using LAS-
4000 Luminescent Image Analyzer and analyzed using the Multi Gauge
software (Fujiﬁlm, Tokyo, Japan).2.6. Hydrodynamic injection of plasmid DNA into mice
Delivery of HBV DNA and expression plasmids into the mouse liver
has been described previously [25]. In brief, 6 to 7-week-old male
BALB/c mice were hydrodynamically injected with 25 μg of plasmid
DNA into the tail veins in a volume of PBS equivalent to 10% of mouse
body weight. The total volume of DNA was delivered into the vein
with high pressure within 4–6 s. Animals were sacriﬁced after 4 days.
Sera were collected for the measurement of HBsAg. Formalin-ﬁxed
or -unﬁxed liver sections were processed for immunohistochemical
analysis to determine HBsAg levels and β-gal activity. The liver tissues
were lysed and HBV DNA was detected by Southern blot analysis as
described above. All procedures involving animal experiments were
approved by the Animal Care Committee, Konkuk University.
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Parafﬁn-embedded liver sections were treated with 3% hydrogen
peroxide and blocked with 5% bovine serum albumin. The sections were
then incubated sequentially with anti-HBs antibodies, biotin-labeled
secondary antibody, and avidin–biotin complex (ABC). Peroxidase stain
was developed with 3,3′-diaminobenzidine (DAB) solution.
2.8. Immunocytochemistry
Levels of nuclear-localized HNF4α proteinwere determined by indi-
rect immunoﬂuorescence analysis. In brief, At 48 h after transfection
with the indicated plasmid, the cells were ﬁxed with 3.7% paraformal-
dehyde (Sigma) for 15 min at room temperature, rinsed with PBS, and
then permeabilized with a 0.1% Triton X-100 solution for 5 min in a
cold chamber. The cells were incubated with anti-Flag antibody and
anti-HNF4α antibody at room temperature for 1 h. After three washes
with PBS, the cells were incubated with Alexa Fluor 350 anti-rabbit
IgG secondary antibody (1:500 dilution) and Alexa Fluor 546 anti-
mouse IgG secondary antibody (1:500 dilution) at room temperature
for 40 min. Fluorescence images were obtained and analyzed using a
Carl Zeiss Axiovert 200microscope and software (Carl Zeiss, Oberkochen,
Germany).
2.9. Luciferase Reporter Assay
HepG2 and Huh-7 cells were transfected with the HBV promoter
construct. At 48 h after transfection, cells were harvested and lysed to
assay using the Luciferase Reporter Assay System (Promega), according
to the manufacturer's instructions. β-Galactosidase activity was mea-
sured for normalization.
2.10. Statistical analysis
Data were analyzed by Student's t-test (p b 0.05, and p b 0.01) and
are shown with standard deviation error bars. p b 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Hepatocystin inhibits both HBx-independent HBV replication
and -dependent HBV replication via the transcriptional regulation of
HBV genome
To evaluate the antiviral activity of hepatocystin against HBV, we
analyzed HBsAg expression and DNA replication in HepG2 cells
cotransfected with HBV1.2 and hepatocystin-expressing plasmids.
Ectopic expression of hepatocystin signiﬁcantly reduced both extra-
cellular and intracellular HBsAg levels (Fig. 1A, B). The level of DNA
replication was also strongly decreased by hepatocystin (Fig. 1B). We
conﬁrmed this effect by treatment with hepatocystin siRNA (20 nM).
Downregulation of endogenous hepatocystin signiﬁcantly increased
the levels of HBsAg expression and viral replication (Fig. 1C).We further
investigatedwhether hepatocystin suppressesHBV in amousemodel in
which HBV1.2 and hepatocystin plasmids were delivered by hydrody-
namic injection. Hepatocystin signiﬁcantly reduced the levels of
HBsAg both in mouse sera (Fig. 1D) and liver tissues (Fig. 1E). Replica-
tion of the HBV genome was also strongly inhibited by ectopic expres-
sion of hepatocystin in mouse livers (Fig. 1F).
Next, we determined whether hepatocystin-mediated inhibition of
HBV replication is HBx-dependent in HepG2 cells. As shown in Fig. 1G,
the replication ability of the HBx-deﬁcient HBV genome was marginal
when compared to the wild-type HBV1.2. In this system, hepatocystin
also inhibited HBsAg expression and viral replication of the HBx-
deﬁcient genome to similar levels as in the wild type HBV1.2 (Fig. 1H).Finally, we examinedwhether hepatocystin suppresses HBV replica-
tion via transcriptional regulation. As shown in Northern blot analysis,
the RNA transcript levels were strongly decreased by hepatocystin
(Fig. 1I). Analysis of HBV enhancer/promoter activity revealed that
hepatocystin signiﬁcantly inhibited the activity of the HBV enhancer/
promoter (Fig. 1J). Therefore, our results indicate that hepatocystin
inhibits both HBx-independent HBV replication and -dependent HBV
replication via the transcriptional regulation of the viral genome.
3.2. Hepatocystin inhibits HBV replication via downregulation of HNF4α
expression
Because HNFs and PGC-1 are essential for the transcriptional regula-
tion of HBV genome [4–7], we investigated whether hepatocystin
affects the expression of HNF1α, HNF3β, HNF4α, and PGC-1 by western
blot analysis. The expression level of HNF4αwas markedly downregu-
lated by hepatocystin in a dose-dependent manner in both HBV1.2-
transfected and non-transfected cells, whereas the expression of
HNF1α, PGC-1, and HNF3β was not affected (Fig. 2A, B). Immunoﬂuo-
rescence analysis conﬁrmed the reduction of HNF4α in the nucleus of
the cells overexpressing hepatocystin (Fig. 2C). We further examined
this effect in hepatocystin-knockdown cells. Downregulation of en-
dogenous hepatocystin strongly increased HNF4α expression levels
(Fig. 2D). Therefore, our results indicate that hepatocystin can regulate
the expression of HNF4α.
To investigate the role of HNF4α in a hepatocystin-mediated antivi-
ral response, we constructed an expression plasmid carrying-HNF4α
and examined the effect of HNF4α on HBV replication in non-hepatic,
HNF4α-deﬁcient 293T cells. As shown in Fig. 2E, ectopic expression of
HNF4α strongly enhanced HBV replication in non-hepatic cells, indicat-
ing that the cloned HNF4α is functionally active. Importantly, the addi-
tion of HNF4α was able to completely restore hepatocystin-mediated
inhibition of HBV replication in HepG2 cells (Fig. 2F). Therefore, our re-
sults indicate that hepatocystin inhibits the replication of HBV via
downregulation of HNF4α.
3.3. Hepatocystin-induced antiviral response is mediated by
ERK1/2-dependent downregulation of HNF4α
MAPK pathway has been shown to inhibit HBV replication via tran-
scriptional regulation [17]. Therefore, we ﬁrst examined whether
hepatocystin induces the activation ofMAPK familymembers, including
ERK1/2, p38, and JNK1/2. Overexpression of hepatocystin markedly
enhanced the phosphorylation of ERK1/2, whereas phosphorylation of
p38 and JNK1/2 was only slightly increased in both HBV1.2-transfected
and non-transfected cells (Fig. 3A, B). We further examined this effect
in hepatocystin-knockdown cells. As shown in Fig. 3C, downregulation
of endogenous hepatocystin inhibited the basal activity of ERK1/2. To
investigate the involvement of MAPK activation on hepatocystin-
mediated antiviral effect to HBV, we examined the antiviral effect in
cells treated with speciﬁc MAPK inhibitors. Treatment with each inhib-
itor effectively inhibited the hepatocystin-induced activation of each
MAPK (Fig. 3D). In this condition, inhibition of ERK1/2 signiﬁcantly re-
stored the hepatocystin-mediated inhibition of HBV promoter activity,
whereas inhibitors of JNK1/2 and p38 had no effect (Fig. 3E).
Hepatocystin-mediated inhibition of HBV replication was also recov-
ered by treatmentwith ERK1/2 inhibitor (Fig. 3F). These results indicate
that the hepatocystin-induced inhibition of HBV transcription is medi-
ated by the activation of ERK1/2. Therefore, we investigated the effect
of hepatocystin-mediated ERK1/2 activation on the regulation of
HNF4α expression. As shown in Fig. 3G, inhibition of ERK1/2 restored
the hepatocystin-induced reduction of HNF4α. This result indicates
that hepatocystin-mediated ERK1/2 activation is responsible for the
downregulation of HNF4α expression.
To further investigate the hepatocystin domain responsible for
ERK1/2 activation and HNF4α downregulation, we examined the level
Fig. 1. Antiviral effects of hepatocystin on HBV gene expression and replication in cultured cells andmouse livers. (A) Effect of hepatocystin on HBsAg secretion in HepG2 cells transiently
cotransfectedwith aHBV1.2 and hepatocystin plasmid for 4 days. (B) Effect of hepatocystin onDNA replication (top) andHBsAg expression (bottom) inHepG2 cells. Numbers under lanes
indicate the relative densitometry results. RC, relaxed circular DNA; DL, double-stranded linear DNA; SS, single-stranded DNA. LHBs, large HBsAg; MHBs, middle HBsAg; SHBs, small
HBsAg; open arrow head, glycosylated HBsAg; closed arrow head, non-glycosylated HBsAg. (C) Effect of hepatocystin knockdown on DNA replication (top) andHBsAg secretion (bottom)
in Huh-7 cells transfected with a HBV1.2 plasmid and hepatocystin siRNA (20 nM). (D–F) Effect of hepatocystin on HBsAg secretion in sera (D), HBsAg expression (E), and HBV DNA rep-
lication (F) inmouse liver tissue hydrodynamically injectedwith HBV1.2 and hepatocystin plasmids. (G) Southern blot analysis of HBV replication in HepG2 cells transfectedwith HBV1.2
or HBx-deﬁcient HBV1.2 (X-) plasmids (top). Expression of HBx protein detected by immunoprecipitation and western blot (bottom). (H) Effect of hepatocystin on HBx-deﬁcient HBV
replication (top) and HBsAg expression (bottom) in HepG2. (I) Northern blot analysis of HBV transcription in HepG2. 18S rRNA was used as loading control. 3.5-kbp RNA, precore and
pregenomic viral RNA; 2.4 and 2.1-kbp RNA, surface RNAs. (J) Analysis of the relative HBV promoter activity in HepG2 cells cotransfectedwith a HBV promoter and hepatocystin plasmids
for 48 h. A schematic diagram of the HBV promoter plasmid is shown on top. **p b0.01 with Student's t-test. Data are representative of three independent experiments.
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Fig. 2. Involvement of HNF4α in hepatocystin-induced antiviral response to HBV. (A) Expression of hepatocyte-enriched transcription factors in HepG2 cells cotransfected with
hepatocystin andHBV1.2 plasmids for 24 h. (B) Effect of hepatocystin on the expression of HNF4α in HBV-free condition. (C) Immunocytochemical analysis of HNF4α expression in nuclei
of HepG2 cells. (D) Effect of hepatocystin knockdown on expression ofHNF4α in Huh-7 cells transfectedwith hepatocystin siRNA (20 nM) for 24 h. (E) Effect of HNF4α onHBV replication
in non-hepatic 293T cells. (F) Effect of HNF4α on hepatocystin-induced antiviral effect in HepG2 cells cotransfected with HBV1.2, hepatocystin, and HNF4α plasmids.
1652 G.-C. Shin et al. / Biochimica et Biophysica Acta 1842 (2014) 1648–1657of ERK1/2 activation and HNF4α expression in HepG2 cells transfected
with different hepatocystin mutant plasmids. Unlike the full-length
hepatocystin, expression of either hepatocystin mutants had no effect
on both ERK1/2 activation and HNF4α expression (Fig. 3H). Indeed,
inhibition of ERK1/2 did not restore the genome replication that was
inhibited by M1 and M2 hepatocystin mutants (Fig. 3I). These results
indicate that the amino-terminal domain (amino acids 1–184) of
hepatocystin is necessary for ERK1/2-dependent repression of HNF4α.
The inhibition of HBV replication bymutants was exerted by interferingFig. 3. Involvement of MAPK signaling in the hepatocystin-induced antiviral response to HBV. (
p38, and JNK1/2 in HepG2 cells cotransfected with hepatocystin and HBV1.2 plasmids for 24 h.
ditions. (D) Effect of hepatocystin knockdown onphosphorylation of ERK1/2 inHuh-7 cells tran
inhibitors. (E) Effect of MAPK inhibitors on hepatocystin-mediated inhibition of HBV promoter
treated with PD98059 (20 μM), SB203580 (20 μM), or SP600125 (20 μM) for 24 h. **p b 0.01. D
hepatocystin-mediated inhibition of HBV replication in HepG2 cells cotransfectedwith HBV1.2
MAPK inhibitor on hepatocystin-mediated repression of HNF4α in HepG2 cells transfected wit
diagram of hepatocystin and its deletion mutants used in this study: signal peptide, SP; compl
retention signal peptide, HDEL (top panel). Effect of mutant hepatocystin on phosphorylation
hepatocystin plasmids (bottom panel). (I) Effect of ERK inhibitor on mutant hepatocystin-medwith the HBx function as previously described [21], not by modulating
this signaling pathway.
3.4. Hepatocystin is important during the IFN-γ-induced antiviral response
To investigate the role of ERK1/2 signaling on IFN-mediated antiviral
response in hepatocyte-derived cells, we examined the HBV promoter
activity and the level of ERK1/2 activation after treatment with IFN-γ.
IFN-γ modestly inhibited the HBV promoter activity in HepG2 cells,A) Effect of hepatocystin on phosphorylation of MAPK family members including ERK1/2,
(B) Effect of hepatocystin on phosphorylation of MAPK family members in HBV-free con-
sfectedwith hepatocystin siRNA. (D) Phosphorylation ofMAPKs in cells treatedwithMAPK
activity in HepG2 cells cotransfected with HBV promoter and hepatocystin plasmids, then
ata are representative of three independent experiments. (F) Effect of MAPK inhibitors on
and hepatocystin plasmids, then treatedwith eachMAPK inhibitor for 3 days. (G) Effect of
h HBV1.2 and hepatocystin plasmids, then treated with PD98059 for 24 h. (H) Schematic
ement-like repeated, CR; mannose 6-phosphate receptor homology, MRH; C-terminal ER
of ERK1/2 and expression of HNF4α in HepG2 cells transfected with HBV1.2 and mutant
iated inhibition of HBV replication.
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1654 G.-C. Shin et al. / Biochimica et Biophysica Acta 1842 (2014) 1648–1657whereas it dramatically inhibited the viral promoter activity in Huh-7
cells (Fig. 4A). The level of ERK1/2 activation by IFN-γ stimulation was
also strongly increased in Huh-7 cells compared with HepG2 cells
(Fig. 4B). We then investigated the involvement of ERK1/2 signaling in
IFN-mediated antiviral effect. Inhibition of ERK1/2 signiﬁcantly restored
the IFN-mediated inhibition of HBV promoter activity inHuh-7 cells, but
had no effect in HepG2 cells (Fig. 4C). These results indicate that the
level of ERK1/2 activation is important for the IFN-mediated inhibition
of viral promoter activity.
To investigate the role of hepatocystin on the IFN-mediated activa-
tion of ERK1/2, we determined the expression level of hepatocystin in
both cells. The expression level of endogenous hepatocystin was higher
in Huh-7 compared with HepG2 cells (Fig. 4D). Therefore, we investi-
gated whether the endogenous level of hepatocystin is associated
with the IFN-γ-induced ERK1/2 activation. In Huh-7 cells where the en-
dogenous level of hepatocystin is high, downregulation of hepatocystin
reduced the IFN-γ-induced activation of ERK1/2 (Fig. 4D, E). In HepG2
cells where the endogenous levels of hepatocystin is relatively low,
the supplementation with hepatocystin led to prolonged and enhanced
activation of ERK1/2 by IFN-γ stimulation (Fig. 4F). We also examined
whether IFN-γ functions with hepatocystin in the repression of HNF4α.
IFN-γ alone showed little effect on HNF4α expression in HepG2 cells;
however, it synergistically reduced the expression of HNF4α in
hepatocystin-overexpressed cells (Fig. 4G). These results indicate that
hepatocystin regulates the IFN-γ-induced ERK1/2 MAPK/HNF4α signal-
ing pathway and its expression level is important for activating this sig-
naling pathway.
We ﬁnally investigated the role of hepatocystin on IFN-γ-mediated
inhibition of HBV replication. Importantly, IFN-γ modestly inhibited
HBV promoter activity and replication in HepG2 cells. However, it
dramatically inhibited viral promoter activity and replication in
hepatocystin-overexpressed cells (Fig. 4H, I). Our data indicate that
the expression level of hepatocystin is important for determining the
susceptibility of HBV to IFN-γ.
4. Discussion
In this study,we found that hepatocystin suppresses HBV replication
both in cultured cells and in mouse livers. This antiviral response
was HBx-independent and mediated by the transcriptional regulation
via the ERK1/2-dependent downregulation of HNF4α. The amino-
terminal domain of hepatocystin is crucial for the modulation of this
antiviral signaling. Furthermore, we found that hepatocystin acts as a
critical component in an IFN-mediated MAPK signaling pathway and
its expression level is important for determining the susceptibility of
HBV to IFN-γ.
Hepatocystin plays a role in regulation of proper folding andmatura-
tion of glycoproteins by forming heterodimers with the alpha catalytic
subunit of glucosidase II in the endoplasmic reticulum (ER) [20]. A recent
study demonstrated that the chaperone-like function of hepatocystin
prevents the Herp-mediated ubiquitination and ER-associated deg-
radation of polycystin-2/TRPP2 [26]. Therefore, we speculated that
hepatocystin may play a role in positively regulating the virus assembly
by affecting the posttranslational process of viral glycoproteins such
as HBsAg. However, our results showed that the overexpression of
hepatocystin reduced both the expression of glycosylated and non-Fig. 4. Role of hepatocystin on IFN-γ-mediated antiviral signaling. (A) Effect of IFN-γ on HBV
++, 500 IU/mL). **p b 0.01. Data are representative of three independent experiments. (B)
with IFN-γ (500 IU/mL). The relative densitometry results of ERK1/2 phosphorylation norm
IFN-γ-mediated inhibition of HBV promoter activity in HepG2 and Huh-7 cells. (D) Expre
down on IFN-γ-induced phosphorylation of ERK1/2 in Huh-7 cells transfected with hepato
expression on IFN-γ-induced phosphorylation of ERK1/2 in HepG2 cells transfected with h
(G) Effect of hepatocystin on IFN-γ-induced repression of HNF4α in HepG2 cells cotransf
hepatocystin on IFN-γ-mediated inhibition of HBV promoter activity in HepG2 cells. (I) E
transfected with HBV1.2 and hepatocystin plasmids, then treated with IFN-γ. Data are repglycosylatedHBsAg in cells aswell as the secretion of HBsAg to the extra-
cellular medium and mouse serum (Fig. 1). Furthermore, by the experi-
ments of Northern blot and promoter assay, we found that hepatocystin
negatively regulates HBV promoter activity. Therefore, we concluded
that hepatocystin mainly functions in the transcriptional regulation of
the HBV genome, eventually inhibiting viral replication.
HNF4α is known to regulate HBV replication by activating the viral
preC/Cpromoter and its enhancers that are critical forHBV transcription
[6]. A recent study using shRNA targeting to HNF4α demonstrated that
it is an essential factor for HBV replication in the cultured cells and
mouse liver [27]. Furthermore, clinical studies using liver tissues from
HBV patients have suggested that the expression level of HNF4α corre-
lates with the occurrence of severe hepatitis B and HBV infection out-
comes [28,29]. Therefore, it is likely that the regulation of HNF4α
expression is important for effective control of HBV replication under
natural infection conditions. In the present study, we showed that over-
expression of hepatocystin reduces HNF4α expression, whereas knock-
down of hepatocystin enhances it. The supplement ofHNF4 restored the
hepatocystin-mediated inhibition of HBV replication. Our results dem-
onstrate that hepatocystin can regulate HNF4α expression, resulting
in the inhibition of HBV replication via transcriptional regulation of
HBV genome.
The expression of HNF4α is modulated by MAPK family members,
especially by ERK1/2 and JNK1/2 [30,31]. Hepatocystin regulates the
activation of the RAS/MAPK signal pathway by binding with activated
ﬁbroblast growth factor receptor and forming a ternary complex with
GRB2 and SOS in neuron and myoblast cells [22,23]. In the present
study, overexpression of hepatocystin activated the MAPK family
members, especially ERK1/2 in hepatocyte-derived cells, whereas
downregulation of hepatocystin inhibited the basal activity of ERK1/2
(Fig. 3). Indeed, pharmacological inhibition of ERK1/2 restored the
hepatocystin-mediated downregulation of HNF4α. Therefore, our re-
sults demonstrate that hepatocystin functions as an upstream regulator
of ERK1/2 activation, which further affects the downregulation of
HNF4α expression in hepatocytes. Recently, Hatzis and coworkers
have demonstrated that the activation of ERK1/2 downregulates
HNF4α expression at the transcriptional level via loss of C/EBPα ex-
pression and concomitant disruption of the HNF4 enhancer–promoter
complex [30]. Therefore, it is likely that the hepatocystin-mediated
downregulation of HNF4α is caused by the similar mechanism as de-
scribed above [30]. A study using constitutively activated Ras reported
that the MAPK pathway is involved in antiviral response against
HBV via transcriptional regulation [17]. We showed that inhibition
of ERK1/2 restored the hepatocystin-induced inhibition of HBV pro-
moter activity and replication. Therefore, we demonstrate that the
hepatocystin/MAPK/HNF4α cascade is a novel pathway involved in
the inhibition of HBV genome transcription.
Hepatocystin, primarily localized in the ER, has an ER localization
signal at the amino-terminal domain and a putative ER retention signal
at the carboxyl-terminal region [20]. Our result also showed that the
full-length hepatocystin was mainly localized in the ER, but two mu-
tants revealed the dispersed expression of hepatocystin throughout
the cytoplasm, probably resulting from the deletion of ER localization
signal at the amino-terminal region (Supplementary Fig. 1). In the
present study, only the full-length hepatocystin induced the ERK1/2-
dependent downregulation of HNF4α expression, while both thepromoter activity in HepG2 or Huh-7 cells after treatment with IFN-γ (+, 250 IU/mL;
Effect of IFN-γ on phosphorylation of ERK1/2 in HepG2 or Huh-7 cells after treatment
alized to total ERK1/2 protein are indicated below each lane. (C) Effect of PD98059 on
ssion level of hepatocystin in HepG2 or Huh-7 cells. (E) Effect of hepatocystin knock-
cystin siRNA (20 nM), then treated with IFN-γ for 1 h. (F) Effect of hepatocystin over-
epatocystin or pcDNA 3.1 plasmids, then treated with IFN-γ for indicated time point.
ected with HBV1.2 and hepatocystin plasmids, then treated with IFN-γ. (H) Effect of
ffect of hepatocystin on IFN-γ-mediated inhibition of HBV replication in HepG2 cells
resentative of three independent experiments.
1655G.-C. Shin et al. / Biochimica et Biophysica Acta 1842 (2014) 1648–1657mutant hepatocystins did not. Collectively, our data indicate that the
ER-associated hepatocystin, not cytoplasmic hepatocystin, is involved
in the activation of ERK1/2, suggesting that hepatocystin may induce
the activation of ERK1/2 independent of forming a ternary complex
with GRB2 and SOS in the cytoplasm. However, how the ER-associatedhepatocystin can modulate the activity of this signaling pathway could
not be elucidated in the present study. Similarly, the ER-associated
calreticulin can also positively regulate the activation of MEK/ERK
signaling pathway through an unknown mechanism, resulting in regu-
lation of cell proliferation and migration [32,33]. Therefore, further
1656 G.-C. Shin et al. / Biochimica et Biophysica Acta 1842 (2014) 1648–1657study for elucidating how ER-associated chaperons can induce the acti-
vation of ERK1/2 is needed.
IFNs can modulate the activity of MAPK family members [15]. A
recent study reported that IFN-β2 reduces the expression of HNF4α
via activation of MAPKs, thereby resulting in inhibition of HBV replica-
tion [31]. Furthermore, IFN-γ reduces the expression of HNF4α, when
cotreated with TNF-α, synergistically inhibiting HBV replication [34].
Therefore, it is likely that MAPK/HNF4α pathway is important for IFN-
mediated inhibition of HBV genome transcription. In the present
study, IFN-γ stimulation showed strong activation of ERK1/2 in Huh-7,
where the endogenous levels of hepatocystin are higher than that in
HepG2 cells. Furthermore, IFN-γ-induced activation of ERK1/2 was re-
duced in hepatocystin-knockdown cells compared with control
cells, whereas it was increased in hepatocystin-overexpressed cells.
Therefore, we found that the expression level of hepatocystin is im-
portant for IFN-mediated activation of ERK1/2 MAPK signaling. Impor-
tantly, we found in the present study that IFN-γmarginally affects the
expression of HNF4α in human hepatocyte-derived cells, but it dramat-
ically inhibits HNF4α expression in cells overexpressing hepatocystin.
Therefore, it is likely that the expression level of hepatocystin is impor-
tant for IFN-mediated antiviral effect via transcriptional regulation of
HBV genome.
The antiviral genes are primarily associated with the regulation
of IFN-α/β and expression of ISGs, resulting in the inhibition of virus
replication. For instance, glucose-regulated protein 78 functions as an
antiviral factor of HBV by upregulating IFN-β and downstream genes
[35]. The cellular inhibitor of apoptosis family protein 2 plays a critical
role in the IFN-production pathway [36]. Hepatocystin alone did not
induce the expression of IFN-α/β gene and downstream ISGs, and it
showed no effect on IFN-induced ISG expression (Supplementary
Fig. 2). The IFN-inducible myeloid differential primary response protein
is involved in the activation of NF-κB, which negatively regulates HBV
replication by accelerating the degradation of pregenomic RNA [37].
Activation of NF-κB pathway exerted an antiviral effect on HBV by
inhibiting the core promoter activity and eliminating the HBV RNA-
containing capsids in the cytoplasm [16,38]. However, hepatocystin
did not induce theNF-κB activation (Supplementary Fig. 2).We demon-
strated that hepatocystin participates in IFN-mediated antiviral re-
sponse independently with IFN-α/β production, JAK/STAT/ISGs, and
the NF-κB signaling pathway.
It has been well-known that other cytokines synergize with IFN-
mediated antiviral response [39]. Combination treatment of IFN-γ and
TNF-α has shown a synergistic effect on antiviral response against HBV
in immortalized mouse hepatocytes [34]. In this study, we conﬁrmed
the synergistic effect of these cytokines in HepG2 cells (Supplementary
Fig. 3A–C). Importantly, we also observed that hepatocystin is inducible
by TNF-α (Supplementary Fig. 3D, E). Furthermore, our results showed
that IFN-mediated inhibition of HBV replication is dramatically increased
in hepatocystin-overexpressed cells comparedwith parent cells (Fig. 4H,
I). Therefore, we speculated that hepatocystin/MAPK/HNF4α pathway
may be crucial for synergizing the antiviral response of various cytokines
during the natural course of HBV infection (Supplementary Fig. 4).
The clinical beneﬁt of anti-TNF-α therapies as a key therapeutic op-
tion for patientswith rheumatoid arthritis, inﬂammatory bowel disease,
and psoriasis has been well-known [40,41]. According to our study,
since the TNF-α-inducible hepatocystin may be crucial for IFN-
mediated control of HBV, it needs to be reminded that the inhibition
of TNF-α pathway can cause a risk for reactivation of HBV or HBV resis-
tance to IFNs in patients with HBV infection.
5. Conclusions
In our previous study, we demonstrated that hepatocystin could
regulate HBV replication by interaction with the HBx protein [21].
Collectively with the present results, we suggest that hepatocystin
plays a critical role in modulating the susceptibility of HBV to variouscytokines at an early stage of HBV infection. We also suggest that
hepatocystin may provide a novel therapeutic approach efﬁciently to
control HBV infection.
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